Abstract COVID‐19 is associated with mitochondrial dysfunction and metabolic abnormalities, including the deficiencies in nicotinamide adenine dinucleotide (NAD + ) and glutathione metabolism. Here it is investigated if administration of a mixture of combined metabolic activators (CMAs) consisting of glutathione and NAD+ precursors can restore metabolic function and thus aid the recovery of COVID‐19 patients. CMAs include l ‐serine, N ‐acetyl‐ l ‐cysteine, nicotinamide riboside, and l ‐carnitine tartrate, salt form of l ‐carnitine. Placebo‐controlled, open‐label phase 2 study and double‐blinded phase 3 clinical trials are conducted to investigate the time of symptom‐free recovery on ambulatory patients using CMAs. The results of both studies show that the time to complete recovery is significantly shorter in the CMA group (6.6 vs 9.3 d) in phase 2 and (5.7 vs 9.2 d) in phase 3 trials compared to placebo group. A comprehensive analysis of the plasma metabolome and proteome reveals major metabolic changes. Plasma levels of proteins and metabolites associated with inflammation and antioxidant metabolism are significantly improved in patients treated with CMAs as compared to placebo. The results show that treating patients infected with COVID‐19 with CMAs lead to a more rapid symptom‐free recovery, suggesting a role for such a therapeutic regime in the treatment of infections leading to respiratory problems. Open‐label phase‐2 and double‐blinded phase‐3 clinical trials show that administration of CMA accelerates the recovery of ambulatory COVID‐19 patients. By integrating clinical data with plasma metabolomics and inflammatory proteomics, it is shown that CMA improves immune response and regulates antioxidant, amino acid, and lipid metabolism. It is observed that administration of CMA is an effective and safe therapeutic strategy for COVID‐19 patients.
【저자키워드】 combined metabolic activators, metabolomics, omics data, proteomics, 【초록키워드】 Treatment, Inflammation, combined metabolic activators, immune response, clinical trial, Phase 2, Infection, nicotinamide, antioxidant, metabolism, COVID‐19, Phase 3 trials, Protein, phase 3 trial, Patient, Placebo, proteome, metabolites, mitochondrial dysfunction, respiratory, metabolite, therapeutic strategy, Amino acid, administration, regulate, lipid metabolism, Plasma levels, Safe, salt, lead, mitochondrial, adenine, glutathione, metabolic abnormalities, complete recovery, changes, deficiency, NAD+, nicotinamide adenine dinucleotide, nicotinamide riboside, Clinical data, ambulatory patients, antioxidant metabolism, CMAs, comprehensive analysis, COVID‐19 patients, deficiencies, double‐blinded phase, glutathione metabolism, inflammatory proteomics, l ‐carnitine, l ‐carnitine tartrate, metabolic function, mixture, Open‐label phase, placebo group, Placebo‐controlled, plasma metabolome, plasma metabolomics, respiratory problems, therapeutic regime, precursor, effective, IMPROVE, shown, significantly, include, investigated, conducted, reveal, accelerate, ambulatory patient, combined metabolic activator, patients treated, phase‐2, phase‐3, Plasma level, significantly shorter, 【제목키워드】 COVID‐19, metabolic, activator, Combined,